Botulinum toxin type a
Dysport, Nuceiva (botulinum toxin type a) is an unknown pharmaceutical. Botulinum toxin type a was first approved as Dysport on 2019-09-27. It is used to treat blepharospasm, dystonia, fissure in ano, genetic skin diseases, and muscle rigidity amongst others in the USA. It has been approved in Europe to treat skin aging.
| Trade Name | Nuceiva |
|---|---|
| Common Name | Botulinum toxin type a |
| Indication | blepharospasm, dystonia, fissure in ano, genetic skin diseases, muscle rigidity, skin aging, strabismus |
| Drug Class | Fluoroquinolone derivatives, nonantibacterial indications (e.g., antineoplastic antibiotics) |
